dioctanoylglycerol pyrophosphate | 676260-27-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: dioctanoylglycerol pyrophosphate
• 英文别名: DGPP；3-{[Hydroxy(phosphonooxy)phosphoryl]oxy}propane-1,2-diyl dioctanoate；[3-[hydroxy(phosphonooxy)phosphoryl]oxy-2-octanoyloxypropyl] octanoate
• CAS: 676260-27-8
• 化学式: C₁₉H₃₈O₁₁P₂
• 分子量: 504.452
• InChiKey: MBDSUZSCJLRKPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  22
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  166
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
  申请人：Miller D. Duane

  公开号：US20060270634A1

  公开（公告）日：2006-11-30

  Disclosed are compositions that modulate the effects of extracellular LPA receptors, the intracellular PPARγ receptor, and autotaxin, and methods for their use.

  揭示了调节细胞外LPA受体、细胞内PPARγ受体和自体脂肪酶效应的组合物，以及它们的使用方法。
• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF
  申请人：Ludwig Institute for Cancer Research, Ltd.

  公开号：EP2654779A1

  公开（公告）日：2013-10-30
• CHEMOEMBOLIZATION AGENTS
  申请人：Bruin Biosciences, Inc.

  公开号：EP3630078A1

  公开（公告）日：2020-04-08
• METHOD FOR ENHANCED NUCLEIC ACID TRANSFECTION USING A PEPTIDE
  申请人：Zhang Yuan

  公开号：US20190307901A1

  公开（公告）日：2019-10-10

  A method for genetic transfection of mammalian cells is disclosed using a novel nanoparticle. The method comprises of mixing cationic peptides to nucleic acids, and then subsequently incorporating this mixture into a liposome with surface modification for transfection purposes and other medical application. With various types of cationic peptides envisioned, the method can be used for developing a nanoparticle comprising of either anionic or cationic liposomes, and for incorporating any type of nucleic acid. The medical application of this technology includes, but not limited to, gene therapy and nucleic acid based vaccination against a broad range of diseases, such as cancer and infectious disease.